{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:00:02Z","timestamp":1790085602258,"version":"4.0.1"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403905"],"award-info":[{"award-number":["82403905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272712"],"award-info":[{"award-number":["82272712"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119906","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:42:36Z","timestamp":1788799356000},"page":"119906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Salvage treatment strategies for recurrence after radical prostatectomy: Current status, challenges, and future directions"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2401-8879","authenticated-orcid":false,"given":"Wang","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3957-1460","authenticated-orcid":false,"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2026.119906_bib1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.juro.2017.08.041","article-title":"Prostate specific antigen testing after radical prostatectomy-can we stop at 20 years?","volume":"199","author":"Ludwig","year":"2018","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119906_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2024.02.024","article-title":"More than words: defining adjuvant, consolidative, and salvage treatment after radical prostatectomy","volume":"86","author":"Lane","year":"2024","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119906_bib4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/JU.0000000000003891","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119906_bib5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1148\/radiol.211824","article-title":"Effect of (18)F-DCFPyL PET\/CT on the management of patients with recurrent prostate cancer: results of a prospective multicenter registry trial","volume":"303","author":"Metser","year":"2022","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.biopha.2026.119906_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2023.05.012","article-title":"Contemporary evaluation of salvage radiotherapy for prostate cancer: radiotherapy dose, field size, and use of hormone therapy","volume":"84","author":"Jiang","year":"2023","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119906_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/JU.0000000000001036","article-title":"Competing risks of mortality among men with biochemical recurrence after radical prostatectomy","volume":"204","author":"Daskivich","year":"2020","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119906_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/JU.0000000000002421","article-title":"Long-term risk of clinical progression utilizing magnetic resonance imaging findings of locally recurrent prostate cancer in patients with biochemical recurrence following radical prostatectomy","volume":"207","author":"Tanaka","year":"2022","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.euo.2020.04.004","article-title":"PSMA-PET\/CT-based lymph node atlas for prostate cancer patients recurring after primary treatment: clinical Implications for salvage radiation therapy","volume":"4","author":"Schiller","year":"2021","journal-title":"Eur. Urol. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119906_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.eururo.2017.07.026","article-title":"Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy","volume":"73","author":"Fossati","year":"2018","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119906_bib11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2019.02.004","article-title":"Assessing the role and optimal duration of hormonal treatment in association with salvage radiation therapy after radical prostatectomy: results from a multi-institutional study","volume":"76","author":"Fossati","year":"2019","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119906_bib12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions","volume":"211","author":"Morgan","year":"2024","journal-title":"J. Urol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119906_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s11912-025-01694-y","article-title":"Defining the role of postoperative radio-Hormone therapy in prostate cancer","volume":"27","author":"Dudipala","year":"2025","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2026.119906_bib14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ijrobp.2025.07.1416","article-title":"Long-term results of NRG\/RTOG 9601, a randomized trial of radiation with or without antiandrogens in patients receiving salvage prostate bed radiation therapy postprostatectomy","volume":"123","author":"Lukka","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"34","key":"10.1016\/j.biopha.2026.119906_bib15","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO-25-01693","article-title":"National cancer institute's working group on biochemically recurrent prostate cancer: clinical trial design considerations","volume":"43","author":"Einstein","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119906_bib16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/JU.0000000000000704","article-title":"Association between postoperative detection of circulating tumor cells and recurrence in patients with prostate cancer","volume":"203","author":"Pak","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2026.119906_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2026.04.014","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer","author":"Tilki","year":"2026","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00259-019-04505-2","article-title":"Prediction nomogram for (68)Ga-PSMA-11 PET\/CT in different clinical settings of PSA failure after radical treatment for prostate cancer","volume":"47","author":"Ceci","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"10.1016\/j.biopha.2026.119906_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/RLU.0000000000002169","article-title":"68Ga-PSMA PET\/CT in patients with biochemical recurrence of prostate cancer: a prospective, 2-center study","volume":"43","author":"Zacho","year":"2018","journal-title":"Clin. Nucl. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119906_bib20","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1007\/s00259-021-05354-8","article-title":"Patterns of disease detection using [(18)F]DCFPyL PET\/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial","volume":"48","author":"Koschel","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"10.1016\/j.biopha.2026.119906_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.eururo.2019.04.016","article-title":"Have we entered the era of imaging before salvage treatment for recurrent prostate cancer?","volume":"76","author":"Devos","year":"2019","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119906_bib22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119906_bib23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119906_bib24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.euo.2021.04.011","article-title":"Integrating prostate-specific antigen kinetics into contemporary predictive nomograms of salvage radiotherapy after radical prostatectomy","volume":"5","author":"Campbell","year":"2022","journal-title":"Eur. Urol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119906_bib25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41379-019-0418-2","article-title":"Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer","volume":"33","author":"Ersv\u00e6r","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.biopha.2026.119906_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111113","article-title":"Refining prognostic stratification in salvage radiotherapy for prostate cancer: a retrospective multicenter cohort study using PSMA-PET and machine learning","volume":"212","author":"Medici","year":"2025","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119906_bib27","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2022.04.048","article-title":"Metastasis-free survival and patterns of distant metastatic disease after prostate-specific membrane antigen positron emission tomography (PSMA-PET)-guided salvage radiation therapy in recurrent or persistent prostate cancer after prostatectomy","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.biopha.2026.119906_bib28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41585-021-00497-7","article-title":"Salvage therapy for prostate cancer after radical prostatectomy","volume":"18","author":"Zaorsky","year":"2021","journal-title":"Nat. Rev. Urol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119906_bib29","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.7150\/thno.18421","article-title":"Diagnostic accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET\/CT before salvage lymph node dissection for recurrent prostate cancer","volume":"7","author":"Jilg","year":"2017","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","article-title":"Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized phase 3 trial (PSMA-SRT NCT03582774)","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119906_bib31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2967\/jnumed.118.225276","article-title":"Detection rate and localization of prostate cancer recurrence using (68)Ga-PSMA-11 PET\/MRI in patients with Low PSA Values \u2264 0.5 ng\/mL","volume":"61","author":"Kranzb\u00fchler","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2026.119906_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111287","article-title":"Detection of local recurrent disease at biochemical failure after prostatectomy by multiparametric MRI versus PSMA PET\/CT within a controlled study","volume":"214","author":"Sanguineti","year":"2026","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119906_bib33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur. Urol. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119906_bib34","doi-asserted-by":"crossref","DOI":"10.1148\/rg.240145","article-title":"Prostate Imaging for recurrence reporting: user guide","volume":"45","author":"Shetty","year":"2025","journal-title":"Radiographics"},{"issue":"2","key":"10.1016\/j.biopha.2026.119906_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2025.7102","article-title":"Five-year outcomes after prostate-specific membrane antigen PET\/CT-guided salvage radiotherapy following radical prostatectomy","volume":"24","author":"Nikitas","year":"2026","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.biopha.2026.119906_bib36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euo.2018.02.008","article-title":"Optimizing the timing of salvage postprostatectomy radiotherapy and the use of concurrent hormonal therapy for prostate cancer","volume":"1","author":"Kishan","year":"2018","journal-title":"Eur. Urol. Oncol."},{"issue":"3 Pt 1","key":"10.1016\/j.biopha.2026.119906_bib38","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.juro.2016.08.106","article-title":"Very early salvage radiotherapy improves distant metastasis-free survival","volume":"197","author":"Abugharib","year":"2017","journal-title":"J. Urol."},{"issue":"10260","key":"10.1016\/j.biopha.2026.119906_bib39","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.biopha.2026.119906_bib40","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119906_bib41","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10260","key":"10.1016\/j.biopha.2026.119906_bib42","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2026.119906_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119906_bib44","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119906_bib45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/pcan.2017.24","article-title":"Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy","volume":"20","author":"Holliday","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.biopha.2026.119906_bib46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.euo.2024.06.013","article-title":"Intensifying salvage therapy in prostate-specific antigen recurrent prostate cancer after radical prostatectomy with apalutamide, salvage radiation, and docetaxel: the phase 2 STARTAR trial","volume":"8","author":"Zhang","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119906_bib47","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial","volume":"41","author":"Tran","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119906_bib48","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2017.11.020","article-title":"Use of concomitant androgen deprivation therapy in patients treated with early salvage radiotherapy for biochemical recurrence after radical prostatectomy: long-term results from a Large, multi-institutional series","volume":"73","author":"Gandaglia","year":"2018","journal-title":"Eur. Urol."},{"issue":"10338","key":"10.1016\/j.biopha.2026.119906_bib49","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2026.119906_bib50","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S1470-2045(21)00242-4","article-title":"Elective nodal radiotherapy in prostate cancer","volume":"22","author":"De Meerleer","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/pcan.2016.54","article-title":"The role of salvage extended lymph node dissection in patients with rising PSA and PET\/CT scan detected nodal recurrence of prostate cancer","volume":"20","author":"Porres","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib52","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2018.09.009","article-title":"Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a Large, multi-institutional analysis","volume":"75","author":"Fossati","year":"2019","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119906_bib53","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.eururo.2018.10.044","article-title":"Nodal oligorecurrent prostate cancer: anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates","volume":"75","author":"De Bruycker","year":"2019","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119906_bib54","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41391-020-00307-y","article-title":"Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience","volume":"24","author":"Boeri","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"6","key":"10.1016\/j.biopha.2026.119906_bib55","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.euo.2024.06.002","article-title":"Current treatment paradigms and clinical outcomes in oligometastatic prostate cancer patients: a targeted literature review","volume":"7","author":"Antonarakis","year":"2024","journal-title":"Eur. Urol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119906_bib56","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(18)30571-0","article-title":"Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group","volume":"19","author":"Lecouvet","year":"2018","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119906_bib57","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2025.07.006","article-title":"Continuous androgen deprivation therapy with or without metastasis-directed therapy for oligometastatic prostate cancer: the multicenter phase 2 randomized EXTEND trial","volume":"88","author":"Sherry","year":"2025","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119906_bib58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2018.12.010","article-title":"Oligometastatic prostate cancer: Is it only a matter of perspective?","volume":"75","author":"Lorenzo","year":"2019","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119906_bib59","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.euo.2024.10.014","article-title":"Combined fixed-duration systemic treatment and metastasis-directed radiotherapy for oligometastatic hormone-sensitive prostate cancer","volume":"8","author":"Ravi","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119906_bib60","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: Reality or figment of imagination?","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119906_bib61","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41391-024-00838-8","article-title":"Prostatectomy in oligometastatic prostate cancer: a call for high-quality evidence","volume":"28","author":"Dorff","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"16","key":"10.1016\/j.biopha.2026.119906_bib62","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119906_bib63","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa2510310","article-title":"Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"394","author":"Shore","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119906_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-026-01096-6","article-title":"PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an \"EMBARK-Like\" cohort","author":"Droghetti","year":"2026","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"9","key":"10.1016\/j.biopha.2026.119906_bib65","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","article-title":"Combination of PARP Inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer","volume":"84","author":"Kostos","year":"2024","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.biopha.2026.119906_bib66","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10459","key":"10.1016\/j.biopha.2026.119906_bib67","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a Change of Androgen Receptor Pathway Inhibitor Therapy for Taxane-Naive Patients with Progressive Metastatic Castration-Resistant Prostate Cancer (PSMAfore): a Phase 3, Randomised, Controlled Trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.biopha.2026.119906_bib68","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jbmr.3618","article-title":"Understanding the bone in cancer metastasis","volume":"33","author":"Fornetti","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2026.119906_bib69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2018.04.014","article-title":"The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer","volume":"68","author":"Saad","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijrobp.2021.06.025","article-title":"Personalized treatment selection leads to low rates of local salvage therapy for bone metastases","volume":"112","author":"Mathis","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.biopha.2026.119906_bib71","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1007\/s00259-016-3386-5","article-title":"Radium-223 dichloride in clinical practice: a review","volume":"43","author":"Florimonte","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2026.119906_bib72","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/bs.acr.2024.07.004","article-title":"Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer","volume":"164","author":"Zhong","year":"2024","journal-title":"Adv. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2026.119906_bib73","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1007\/s00259-024-06685-y","article-title":"Whole-body tumour burden on [18F]DCFPyL PET\/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics","volume":"51","author":"Garc\u00eda-Zoghby","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2026.119906_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110476","article-title":"Undetectable PSA predicts outcome after salvage radiotherapy for biochemical recurrence following radical prostatectomy","volume":"200","author":"Scharl","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119906_bib75","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.121.262412","article-title":"A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients","volume":"63","author":"Abghari-Gerst","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119906_bib76","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eururo.2017.11.012","article-title":"Multiparametric magnetic resonance imaging is an independent predictor of salvage radiotherapy outcomes after radical prostatectomy","volume":"73","author":"Sharma","year":"2018","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","article-title":"Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery","volume":"83","author":"Knipper","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2026.119906_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110532","article-title":"Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database","volume":"201","author":"Pommier","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119906_bib79","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2967\/jnumed.125.269996","article-title":"The Use of PSMA PET\/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country","volume":"66","author":"Mogensen","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119906_bib80","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG\/RTOG 9601 Randomized Clinical Trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119906_bib81","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.euo.2024.06.008","article-title":"PTEN Loss Is Associated with Adverse Outcomes in the Setting of Salvage Radiation Therapy","volume":"7","author":"Lee","year":"2024","journal-title":"Eur. Urol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib82","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.euf.2023.07.004","article-title":"Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy","volume":"10","author":"Sabbagh","year":"2024","journal-title":"Eur. Urol. Focus."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib83","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.semnuclmed.2023.06.001","article-title":"Applications of Artificial Intelligence in PSMA PET\/CT for Prostate Cancer Imaging","volume":"54","author":"Lindgren Belal","year":"2024","journal-title":"Semin. Nucl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib84","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and Clinical Activity of BMS-986365 (CC-94676), a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann. Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2026.119906_bib85","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study","volume":"43","author":"Stein","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119906_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.124308","article-title":"Alendronate Conjugate for Targeted Delivery to Bone-Forming Prostate Cancer","volume":"256","author":"Damasco","year":"2023","journal-title":"Talanta"},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib87","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/10717544.2022.2050845","article-title":"Bone-Targeted Nanoplatform Enables Efficient Modulation of Bone Tumor Microenvironment for Prostate Cancer Bone Metastasis Treatment","volume":"29","author":"Zhang","year":"2022","journal-title":"Drug. Deliv."},{"issue":"9","key":"10.1016\/j.biopha.2026.119906_bib88","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/1535-7163.MCT-17-1002","article-title":"Recombinant MDA-7\/IL24 Suppresses Prostate Cancer Bone Metastasis through Downregulation of the Akt\/Mcl-1 Pathway","volume":"17","author":"Pradhan","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119906_bib89","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.MCT-19-0387","article-title":"A Novel Salicylanilide Derivative Induces Autophagy Cell Death in Castration-Resistant Prostate Cancer via ER Stress-Activated PERK Signaling Pathway","volume":"19","author":"Hsieh","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"17","key":"10.1016\/j.biopha.2026.119906_bib90","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1021\/acs.jmedchem.3c01294","article-title":"Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy","volume":"66","author":"Zha","year":"2023","journal-title":"J. Med. Chem."},{"issue":"10442","key":"10.1016\/j.biopha.2026.119906_bib91","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"issue":"10442","key":"10.1016\/j.biopha.2026.119906_bib92","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600942X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600942X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:04:22Z","timestamp":1790082262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222600942X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":92,"alternative-id":["S075333222600942X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119906","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage treatment strategies for recurrence after radical prostatectomy: Current status, challenges, and future directions","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119906"}}